REF-188 · Jäger et al., 2025 (ISSN) · Journal of the International Society of Sports Nutrition · Paper · PubMed

ISSN Position Stand: Long-Chain Omega-3 Polyunsaturated Fatty Acids

Astrong evidenceMeasured on a mixed groupWritten before October 2026, being re-checked

Key Findings — Official ISSN positions (from the abstract)

1

Athletes may be at a higher risk for omega-3 PUFA insufficiency.

2

Diets rich in omega-3 PUFA, including supplements, are effective for raising omega-3 PUFA levels.

3

Omega-3 supplementation, particularly EPA and DHA, has been shown to enhance endurance capacity and cardiovascular function during aerobic-type exercise.

4

Omega-3 supplementation may not confer a muscle-hypertrophic benefit in young adults.

5

Combined with resistance training, omega-3 may improve strength in a dose- and duration-dependent manner.

6

Omega-3 may decrease subjective measures of muscle soreness after intense exercise.

7

Omega-3 can positively affect various immune-cell responses in athletic populations.

8

Prophylactic omega-3 may offer neuroprotective benefits to athletes exposed to repeated head impacts.

9

Omega-3 supplementation is associated with improved sleep quality.

10

Omega-3 PUFA are classified as prebiotics, but gut-microbiome studies in athletes are lacking.

The abstract gives no doses, durations, effect sizes or per-claim evidence grades; the position stand's dosing discussion is in the full text and has not been checked against the abstract.

Practical Application

The ISSN's official position: athletes may be at higher risk of omega-3 insufficiency; EPA/DHA supplementation has been shown to enhance endurance capacity and cardiovascular function during aerobic exercise, may reduce subjective muscle soreness after intense exercise, may improve strength when combined with resistance training (dose- and duration-dependent), is associated with better sleep quality, and does not appear to add muscle hypertrophy in young adults (position stand, ISSN 2025).
For an endurance athlete the case is recovery and cardiovascular function, not a direct power gain: the stand does not quantify a performance effect, and percentage gains quoted in earlier versions of this entry had no source.
Soreness and sleep are the two effects an athlete can plausibly notice; treat them as the reason to try it, and judge by those.
Not from this paper; the base's own practice: a combined EPA+DHA intake in the low-gram range per day, taken with food, for at least several weeks before judging any effect, with the Omega-3 Index as the objective check where a blood test is available. Specific milligram doses, ratios and targets are the base's practice, not the abstract's; see REF-189 for why trial doses and durations are too heterogeneous to state a single evidence-based dose.
Mechanistic route (see REF-190): lower heart rate and whole-body and myocardial oxygen demand at a given workload after fish oil in trained cyclists — consistent with the "cardiovascular function" position.

Limitations

From the design as the abstract reports it: a position stand based on a critical examination of the literature — expert consensus, not a new pooled analysis; the abstract gives no doses, durations, effect sizes or per-conclusion evidence grades.
Several positions are hedged in the abstract itself: sleep quality is an association ("is associated with"), and the soreness, strength, hypertrophy and neuroprotection statements use "may".
The authors note that studies on the gut microbiome and gut health in athletes are currently lacking.
The conclusions cover healthy and athletic populations together; the abstract does not separate endurance athletes from other groups.
How this entry was checked and changed
Content correction 2026-09-27
Effects table with doses (2400 mg EPA + 1200 mg DHA), durations (≥4 wk, 5-7 d, ≥8 wk) and per-row evidence grades deleted: none of it is in the abstract.
"ISSN recommendation: EPA 2-3 g + DHA 1-2 g = 3-5 g/day, ratio 2:1-3:1, minimum 4 weeks" deleted as a stated recommendation; dosing kept only as the base's own practice without figures.
14-week supplementation plan, brand list, cost, "expected gains" (+3-5% endurance, −30-40% TNF-α, −25% soreness, +2-3% cardiac output) and Omega-3 Index targets (>8%, ~4%) deleted: not from the paper.
Mechanisms section (resolvins, membrane fluidity, NO) removed: not in the abstract. Added the abstract's ten official positions verbatim in substance, including the negative one (no hypertrophy benefit in young adults).
Cross-reference label: REF-141 is Jones & Kirby's resilience paper, not Laursen 2007.
Cross-references to duplicate stubs repointed to their canonical entries (REF-162->REF-306); the stubs were emptied on 2026-09-27.
Cross-reference descriptions checked against the cited entries' current content; wrong years, wrong entries and claims the cited entry does not make were corrected.
2026-09-28: added Limitations from the abstract (Europe PMC PMID 39810703).